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Current treatment approaches for posttraumatic stress
disorder (PTSD) include the use of medications, psy-
chotherapy, or a combination of both, but they are
limited in their effectiveness as only some have access
to or are able to tolerate exposure therapy, and phar-
macotherapy is largely nonspecific and only partially
effective. As PTSD incurs substantial cost both to indi-
viduals (e.g., disruptions in daily life functioning,
health status, and well-being) and to society (with ele-
vated rates of substance use, hospitalization, and suici-
dal behavior), the development of more effective
pharmacological treatments is critical and requires a
better understanding of the neurobiological mecha-
nisms implicated in the pathogenesis of PTSD. Kel-
mendi, Adams, Southwick, Abdallah, and Krystal
(2017) provide a comprehensive review of neurotrans-
mitter systems implicated in PTSD and highlight that
the understanding of neurotransmitters and the modu-
latory systems involved is essential for sophisticated use
of pharmacotherapy in PTSD. It is important, how-
ever, to take into consideration that neurotransmitter
“abnormalities” occur within an anatomical/functional
context, that is within specific neural circuits, which
perform specific functions and thus lead to specific
symptoms. For example, exaggerated norepinephrine
(NE) in the amygdala might lead to one symptom, but
exaggerated NE secretion in the hippocampus or pre-
frontal cortex might lead to a different set of symp-
toms. Thus, understanding the role of neural circuits
involved in different intermediate phenotypes and dis-
order subtypes (Liberzon & Abelson, 2016) will be
critical for designing more specific treatment
approaches. Further, the fact that dysfunction in neu-
rotransmitter systems can be affected by an individual’s
genetic factors has been gaining increased attention,
and related concepts have led to the development of
“personalized medicine” in other fields, such as cancer
therapy. Certain genotypes, or epigenetic processes,
such as DNA methylation, or histone acetylation, can
not only constitute risk or resilience factors for PTSD
development, but may also serve as the biomarkers of
outcomes of specific treatments. Kelmendi et al.
(2017) briefly mention the role of individual genetic
profiles, in the context of limited efficacy and lack of
specificity of available PTSD treatments, but we
believe these important topics deserve further atten-
tion, as they have critical implications for clinical prac-
tice. We also mention another important factor that
was not directly addressed in the review by Kelmendi
et al., but we believe should be considered in develop-
ing effective treatment approaches, which is the timing
of an intervention, within the dynamics of PTSD
development.
NEUROCIRCUITRY-BASED MODELS OF PTSD: REPRESENTING
ALTERED BRAIN FUNCTIONS AND DIFFERENT INTERMEDIATE
PHENOTYPES
As noted by Kelmendi et al. (2017), dysregulations on
an anatomical level lie within distinct neural systems.
Advances in affective neuroscience in the last decade
have unveiled specific neural systems (neurocircuits)
implicated in PTSD development, as well as some
of the underlying molecular/cellular mechanisms
involved. These include fear learning (FL), threat
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detection (TD), emotion regulation (ER), and context
processing (CP) systems. These dedicated systems/cir-
cuits serve distinct brain functions and are associated
with subsets of biological abnormalities that are likely
to explain different aspects of PTSD. Liberzon and
Abelson (2016) also suggested that FL, TD, ER, and
CP might correspond to specific PTSD subtypes if
PTSD indeed represents a collection of somewhat dis-
tinct neurobiological entities. An understanding of neu-
rocircuits, and underlying mechanisms involved in
them, may be useful for developing a more specific
and personalized treatment approach; a specific treat-
ment (e.g., medication, therapy, or a combination of
both) can be chosen based on the dominant phenotype
in a given patient, which will in turn enhance the
effectiveness of the chosen treatment.
NEURAL CIRCUITS: BRAIN REGIONS AND FUNCTIONS
Among these, FL circuitry governs fear acquisition,
fear extinction, and fear generalization. PTSD is char-
acterized by a diminished ability to learn that some-
thing once dangerous is now safe (i.e., altered fear
extinction), and to discriminate between dangerous
and safe cues (i.e., overgeneralization pattern). More
specifically, these processes involve the basolateral
complex of the amygdala (BLC), which receives sen-
sory information (input) from the thalamus and is
where fear/safety learning takes place. The amygdala
and BLC subnetworks are interconnected with the
ventral medial prefrontal cortex (vmPFC) and the hip-
pocampus, and work in conjunction to regulate fear/
extinction learning. Indeed, impaired extinction recall
in PTSD is manifested in hyperactivation of amygdala
and hypoactivation of mPFC, raising the possibility
that the fear learning deficit in PTSD might stem from
extra amygdala regulatory regions (Liberzon &
Abelson, 2016).
Threat detection circuitry governs the more general
ability to detect salient cues in the environment,
whether positive or negative, and TD abnormalities
could lead to hypervigilance, preferential processing of
trauma cues, and more. The insula/operculum, dorsal
anterior cingulate (dACC), and amygdala are key struc-
tures in TD circuitry, with the dACC participating in
error and conflict detection, whereas the insula is
linked to anticipation and monitoring the internal
states. Together, these highly interconnected regions
constitute a salience network (SN), a circuit that is
responsible for detecting and orienting to salient stim-
uli. Indeed, PTSD is associated with attentional bias
toward threat, and with increased connectivity within
SN, and is also associated with hyperactivation of the
insula, amygdala, and dACC on various tasks.
Emotion regulation circuitry encompasses one’s abil-
ity to modulate emotions (responses to stimuli) by
engaging higher cognitive/executive function (EF), like
redirecting attention away from emotional stimuli, or
deploying different strategies such as cognitive reap-
praisal, distancing, or suppression of emotion. ER cir-
cuitry includes prefrontal cortical regions: dorsolateral,
ventrolateral, lateral orbifrontal, and dorsomedial PFC,
as well as dACC. PTSD is characterized by exaggerated
emotional responses, heightened impulsivity, and irri-
tability that can arise if ER circuitry is dysfunctional.
Indeed, PTSD has been associated with diminished
ability for cognitive reappraisal and has been linked to
decreased activation of dorsolateral and dorsomedial
PFC. Specific cellular and molecular mechanisms that
might lead to deficits in TD and ER circuits need to
be identified in order to better understand their contri-
bution to PTSD symptoms, and to facilitate approaches
to treatment.
Context processing circuitry is responsible for repre-
sentation and retrieval of more general information in
the environment and modulates our responses to a par-
ticular cue to best fit the current situation. CP also
“supports” fear conditioning and fear extinction by
guiding our responses to the cue, based on the context
within which the cue occurs. In PTSD, deficits in CP
could lead to dominance of fear over safety memories,
or hypervigilance. The hippocampus is a key structure
implicated in CP and is thought to be responsible for
context encoding. The hippocampus is connected with
the mPFC, which also plays a significant role in con-
text processing (and consequently, in fear learning,
extinction, and memory consolidation). More specifi-
cally, the mPFC is responsible for learning associations
between context and corresponding adaptive responses,
particularly emotional responses. PTSD is associated
with hypoactivity of the vmPFC and hippocampus, as
well as diminished connectivity between the regions.
Glucocorticoid signaling in the hippocampus as well as
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glutamatergic transmission in prefrontal regions might
be involved in context processing deficits.
Understanding of the aforementioned neural circuits
and mechanisms involved creates an opportunity to
develop treatments that target these circuits. For exam-
ple, abnormalities in FL circuitry can be targeted by
combining exposure therapy and cannabinoids. Expo-
sure therapy enhances the process of fear extinction,
while cannabinoids can facilitate extinction memory
formation. CP circuitry deficits (specifically, hypoacti-
vation of the mPFC) could be amenable to glutamater-
gic transmission modulation (e.g., ketamine
administration) in combination with contextual pro-
cessing “retraining.” Disruption in hippocampal func-
tion, which impairs contextual processing, might be
responsive to neuro- or synaptogenesis enhancing
agents or behaviors (novelty/exercise). Dysfunction
within ER circuitry might be treated by psychothera-
peutic approaches that practice emotional regulation
strategies, or by agents such as paroxetine, which has
been shown to increase recruitment of prefrontal
regions. Thus, while we agree with the authors that
identification of “subtypes” of PTSD can improve
treatment approaches, a more granular understanding of
neural circuits involved will be required for the devel-
opment of “personalized” treatment, which targets a
dominant phenotype and altered neural circuitry, in an
individual patient.
GENETIC FACTORS AND PTSD TREATMENT
The genetic risk factors for PTSD development are still
unknown (although major international collaboration is
underway to uncover the genetic architecture of
PTSD), and current treatment approaches to PTSD are
yet to include genotype-based precision medicine, cur-
rently used in other medical specialties. The statement
by Kelmendi et al. (2017, p. 3) that “limited efficacy
of SSRIs in the treatment of PTSD must be under-
stood in terms of variable individual genetic profile” is
appropriate, and we argue that genetic aspects in PTSD
treatment deserve further elaboration. If we are to learn
from our colleagues in medical subspecialties, an
understanding of an individual’s genotypes has the
potential to significantly influence treatment selection
and can therefore enhance the effectiveness of an inter-
vention. As genotyping becomes more affordable, our
field can rapidly capitalize on this progress, and we can
use genotyping in clinical trials.
GENETICS AND TREATMENT RESPONSE
Some specific examples of genetic factors in PTSD
pharmacotherapy involve genetic variants in the (a) 5-
HTTLPR serotonin-transporter-linked polymorphic
region, which is involved in serotonin secretion and
linked to amygdala activation; (b) BDNF (brain-
derived neurotrophic factor), involved in hippocampal
neurogenesis, synaptic plasticity, and thus, memory
consolidation and learning; and (c) FKBP5 glucocorti-
coid receptor chaperone protein that together with
heat shock proteins participates in glucocorticoid
receptor transport to the nucleus and, thus, can affect
glucocorticoid sensitivity. Bryant et al. (2010) reported
that LL carriers of 5-HTTLPR respond more favorably
to sertraline treatment and to cognitive-behavioral
therapy (CBT) compared to S allele carriers. If, as sug-
gested, the 5-HTTLPR S allele is associated with
reduced efficiency of the serotonin-transporter protein
and hyperactivation of the amygdala, S carriers might
have more difficulty implementing adaptive fear-
related processing necessary for treatment. Similarly, it
was reported that the Met allele carriers (Met/Met and
Val/Met genotypes) of the BDNF gene respond less
favorably to CBT than the Val allele carriers, poten-
tially due to differential BDNF secretion in the hip-
pocampus. Finally, the T-allele carriers of the FKBP5
genotype, which has been linked to increased gluco-
corticoid receptor sensitivity and lower cortisol
responses, respond less favorably to narrative exposure
therapy (NET; Wilker et al., 2014). As NET involves
trauma memory exposure, shortened cortisol response
might alter fear extinction efficacy. Here, the differ-
ences in therapy outcomes were noted after
10 months, but not immediately posttreatment, high-
lighting the importance of the time-dependent dynam-
ics in this process. Finally, initial evidence of
epigenetic effects on PTSD treatment has been emerg-
ing, with Yehuda et al. (2013) reporting that higher
pretreatment glucocorticoid receptor (GR) promoter
exon 1F promoter methylation predicts positive treat-
ment response to prolonged exposure psychotherapy.
Although these all are preliminary findings in small
samples that require replication, we believe they herald
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the arrival of genotype-based precision medicine to
psychiatry in general, and PTSD in particular, in the
near future.
OPTIMAL TIMING AND TEMPORAL DYNAMICS OF PTSD
DEVELOPMENT
In addition to identifying and targeting intermediate
phenotypes, or to implementing genotype-based treat-
ment selection procedures, it might also be useful to
consider both the temporal dynamics of PTSD devel-
opment, as well as optimal timing for a particular treat-
ment. With respect to PTSD development, several
stages can be identified: (a) preexisting vulnerability
stage (genetic or environmental risks), when prevention
strategies that limit trauma exposure for vulnerable
individuals, or resilience enhancement, can take place;
(b) early posttrauma exposure, when fear learning/
safety consolidation take place, which allows for an
opportunity for secondary prevention; and (c) disorder
stage, when the full PTSD phenotype is expressed, and
treatment of PTSD-specific pathophysiology can occur.
Treatment efficacy will depend on the match between
the drug’s mechanism of action and the specific patho-
physiologic process taking place at the time of adminis-
tration. Thus, effective treatment approaches to these
various stages will likely differ, with pharmacotherapy
relevant mainly to the two later stages. Temporal
aspects might be even more important within a partic-
ular stage—for example, the use of the beta blocker
(adrenoreceptor beta) propranolol to weaken consolida-
tion of trauma memories, which involves a time win-
dow of 6 hours following trauma exposure for
administration to take place. Although the use of pro-
pranolol is still debated and under investigation, these
examples highlight the potential importance of
considering temporal dynamics in pharmacotherapeutic
approaches to PTSD. Due to limited efficacy of current
treatment practices and the high individual and societal
costs of PTSD, designing more effective treatment
approaches is crucial. The review by Kelmendi et al.
(2017) provides an analysis of neurotransmitter systems
and the alterations found in these systems in PTSD,
which is essential for the development of effective
pharmacological agents. In this commentary, we discuss
three additional considerations that are likely to
improve current treatment practices. These involve the
consideration of neural circuits that can shape specific
subtypes of PTSD or highlight involvement of specific
systems in a given patient, consideration of known
genetic factors that will likely improve treatment selec-
tion in the near future, and lastly, consideration of
temporal aspects of both the pathophysiology and the
treatment administration.
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